This is a multi-center, single-arm, non-randomized, prospective clinical study. The clinical study is designed as a non-inferiority study to assess the effectiveness of the Aurora Endometrial Ablation System compared to an objective standard. Safety will be evaluated by determining the number and percentage of subjects who experience one or more of serious adverse events.

Inclusion Criteria:

1. Refractory menorrhagia with no definable organic cause

2. Female subject from age 25 to 50 years

3. Uterine sound measurement of 6.0cm to 10.0cm (external os to internal fundus)

4. One of the following criteria:

   A. Documented history of menorrhagia secondary to dysfunctional uterine bleeding (DUB).

   B. If a pictorial blood loss assessment chart (PBLAC) scoring systems is used; a minimum PBLAC score of ≥150 for 1 month prior to study enrollment.

5. Premenopausal at enrollment as determined by FSH measurement ≤ 40 IU/ml

6. Not pregnant and no desire to be pregnant in the future

7. Patient agrees not to use hormonal contraception or any other medical intervention for bleeding during the study

8. Able to provide written informed consent using a form that has been approved by the reviewing IRB/EC

9. Subject agrees to follow-up exams and data collection, including ability to accurately use menstrual diaries for PBLAC analysis.

10. Subject who is literate or demonstrates an understanding on how to use menstrual diaries.

Exclusion Criteria:

1. Pregnancy or subject with a desire to conceive

2. Endometrial hyperplasia as confirmed by histology

3. Presence of active endometritis

4. Active pelvic inflammatory disease

5. Active sexually transmitted disease (STD), at the time of ablation. Note: Treatment of STD documented in the chart serves as sufficient evidence of infection resolution. Patient may be considered for study enrollment.

6. Presence of bacteremia, sepsis, or other active systemic infection

7. Active infection of the genitals, vagina, cervix, uterus or urinary tract at the time of the procedure

8. Known/suspected gynecological malignancy within the past 5 years

9. Known clotting defects or bleeding disorders

10. Untreated/unevaluated cervical dysplasia (except CIN I)

11. Known/suspected abdominal/pelvic cancer

12. Prior uterine surgery (except low segment cesarean section) that interrupts the integrity of the uterine wall (e.g., myomectomy or classical cesarean section)

13. Previous endometrial ablation procedure

14. Currently on medications that could thin the myometrial muscle, such as long-term steroid use (except inhaler or nasal therapy for asthma)

15. Currently on anticoagulants

16. Abnormal or obstructed cavity as confirmed by hysteroscopy or SIS, specifically:

    1. Septate or bicornuate uterus or other congenital malformation of the uterine cavity
    2. Pedunculated or submucosal myomas distorting the uterine cavity
    3. Polyps likely to be the cause of the subject's menorrhagia
    4. Intramural or subserosal myomas that distort the uterine cavity

17. Presence of an intrauterine device (IUD) which the patient is unwilling to have removed at the time of the operative visit

18. Presence of an implantable contraceptive device (e.g. Essure or Adiana).

19. Subject currently on hormonal birth control therapy or unwilling to use a non-hormonal birth control post-ablation (including a Mirena device).

20. Subject who is within 6-weeks post partum.

21. Any general health condition which, in the opinion of the Investigator, could represent an increased risk for the subject

22. Any subject who is currently participating or considers future participation in any other research of an investigational drug or device.

Subjects Treated

1 year

All Adverse Events observed during the clinical study, regardless of relationship to the study device or procedure are reported below.